Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
McKinsey
Johnson and Johnson
Dow

Last Updated: January 21, 2022

Volunteer for clinical trials for TRIESENCE at ClinicalTrialExchange

DrugPatentWatch Database Preview

TRIESENCE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Triesence patents expire, and when can generic versions of Triesence launch?

Triesence is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

Summary for TRIESENCE
Drug patent expirations by year for TRIESENCE
Drug Prices for TRIESENCE

See drug prices for TRIESENCE

Recent Clinical Trials for TRIESENCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 4
Duke UniversityN/A
Bausch & Lomb IncorporatedN/A

See all TRIESENCE clinical trials

Pharmacology for TRIESENCE

US Patents and Regulatory Information for TRIESENCE

TRIESENCE is protected by three US patents.

Patents protecting TRIESENCE

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF OPHTHALMIC DISORDERS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Novartis TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Colorcon
Merck
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.